Inhibition of the MLL1-WDR5 interaction modulates epithelial to mesenchymal transition and metabolic pathways in triple-negative breast cancer cells

被引:0
作者
Sarkar, Shilpi [1 ]
Kandasamy, Thirukumaran [1 ]
Ghosh, Siddhartha Sankar [1 ,2 ]
机构
[1] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 39, Assam, India
[2] Indian Inst Technol Guwahati, Ctr Nanotechnol, Gauhati 39, Assam, India
关键词
Histone methylation; Triple-negative breast cancer; MLL1; Epithelial to mesenchymal transition; Metabolic reprogramming; PLASTICITY;
D O I
10.1016/j.bbrc.2025.151559
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone methylation is a key epigenetic modulation that regulates gene expression and is often associated with the pathogenesis of various cancers, including triple-negative breast cancer (TNBC). Histone methyltransferase, MLL1-WDR5 complex regulates gene transcription by catalyzing trimethylation of lysine 4 on histone H3 (H3K4me3) and promotes carcinogenesis. Herein, epithelial-to-mesenchymal transition (EMT) in TNBC cells is shown to facilitate upregulation of MLL1 and WDR5 expression by 4.7-fold and 3.84-fold, thereby establishing the association of these proteins in EMT dynamics. Therefore, we explored the therapeutic potential of inhibiting MLL1-WDR5 interaction using the small molecule inhibitor MM-102 in TNBC cell lines. MLL1 inhibition significantly reduced H3K4me3 levels and enhanced the apoptotic population by 30 % in MDA-MB-468 cells, demonstrating its cytotoxic potential. Notably, MM-102 treatment reverses the EMT process by upregulating the expression of epithelial markers (such as E-cadherin and claudin) and downregulating the expression of mesenchymal markers (such as beta-catenin, Slug, caveolin 1, and fibronectin). In addition, MLL1 inhibition caused a metabolic shift, with a 5-fold increase in ALDO A and a 4-fold increase in ENO1 expression, indicating enhanced glycolysis. Further reduction in the fatty acid uptake and lipid droplet accumulation by MM-102 treatment signifies that targeting MLL1 also rewires the metabolic network in TNBC cells. Collectively, inhibiting MLL1 represents a promising therapeutic strategy for managing EMT-driven metastasis, reshaping metabolic reprogramming, and ultimately improving therapeutic outcomes in aggressive breast cancer.
引用
收藏
页数:13
相关论文
共 50 条
[41]   miR-30a inhibits epithelial-mesenchymal transition and metastasis in triple-negative breast cancer by targeting ROR1 [J].
Wang, Xin ;
Qiu, Huisi ;
Tang, Ruiming ;
Song, Huisheng ;
Pan, Huilin ;
Feng, Zhengfu ;
Chen, Longhua .
ONCOLOGY REPORTS, 2018, 39 (06) :2635-2643
[42]   TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype [J].
Rahman, Monzur ;
Davis, Sean R. ;
Pumphrey, Janet G. ;
Bao, Jing ;
Nau, Marion M. ;
Meltzer, Paul S. ;
Lipkowitz, Stanley .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (02) :217-230
[43]   TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype [J].
Monzur Rahman ;
Sean R. Davis ;
Janet G. Pumphrey ;
Jing Bao ;
Marion M. Nau ;
Paul S. Meltzer ;
Stanley Lipkowitz .
Breast Cancer Research and Treatment, 2009, 113 :217-230
[44]   AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells [J].
Zajac, Olivier ;
Leclere, Renaud ;
Nicolas, Andre ;
Meseure, Didier ;
Marchio, Caterina ;
Vincent-Salomon, Anne ;
Roman-Roman, Sergio ;
Schoumacher, Marie ;
Dubois, Thierry .
CELLS, 2020, 9 (01)
[45]   Mesenchymal stem cell-derived exosomes enriched with miR-218 reduce the epithelial–mesenchymal transition and angiogenesis in triple-negative breast cancer cells [J].
Samaneh Shojaei ;
Maryam Moradi-Chaleshtori ;
Mahdi Paryan ;
Ameneh Koochaki ;
Kazem Sharifi ;
Samira Mohammadi-Yeganeh .
European Journal of Medical Research, 28
[46]   Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells [J].
You, Kyu Sic ;
Yi, Yong Weon ;
Kwak, Sahng-June ;
Seong, Yeon-Sun .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (03) :828-840
[47]   Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer [J].
Haque, Mazharul ;
Shyanti, Ritis K. ;
Mishra, Manoj K. .
FRONTIERS IN ONCOLOGY, 2024, 14
[48]   Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states [J].
Sulaiman, Andrew ;
McGarry, Sarah ;
Li, Li ;
Jia, Deyong ;
Ooi, Sarah ;
Addison, Christina ;
Dimitroulakos, Jim ;
Arnaout, Angel ;
Nessim, Carolyn ;
Yao, Zemin ;
Ji, Guang ;
Song, Haiyan ;
Gadde, Suresh ;
Li, Xuguang ;
Wang, Lisheng .
MOLECULAR ONCOLOGY, 2018, 12 (04) :423-440
[49]   AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer [J].
Zhang, Kaiming ;
Liu, Peng ;
Tang, Hailin ;
Xie, Xiaoming ;
Kong, Yanan ;
Song, Cailu ;
Qiu, Xingsheng ;
Xiao, Xiangsheng .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[50]   Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer [J].
Lv, Zhi-Dong ;
Yang, Zhao-Chuan ;
Liu, Xiang-Ping ;
Jin, Li-Ying ;
Dong, Qian ;
Qu, Hui-Li ;
Li, Fu-Nian ;
Kong, Bin ;
Sun, Jiao ;
Zhao, Jiao-Jiao ;
Wang, Hai-Bo .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (09) :1640-1650